Dr. Salim Dhanji reports

ME THERAPEUTICS HOLDINGS INC. RECEIVES FUNDING SUPPORT FOR PRECLINICAL TESTING OF PRODRUG CANDIDATES

ME Therapeutics Holdings Inc. is receiving advisory services and up to $50,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the preclinical testing of its myeloid-targeted pro-drug candidates. The funding will support the manufacture and testing of the prodrug candidates in selected mouse cancer models. We are extremely pleased that NRC IRAP has chosen to support this project as it provides an opportunity for the Company to continue to expand the scope of our prodrug candidate development program by allowing for their testing in more preclinical in vivo cancer models.

ME Therapeutics novel small molecule prodrug candidates are designed to specifically target suppressive myeloid cells in the tumour environment. The active component of these prodrug candidates has been shown to interfere with several key pathways involved in immune suppression and cancer growth. Since the prodrug candidates target the immune system rather than the cancer cells, the Company believes they may be useful for several distinct cancer types. Testing of these candidates in multiple in vivo cancer models will help the Company determine which cancers may be amenable to treatment with the prodrug candidates.

ME Therapeutics Holdings Inc.

ME Therapeutics is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity. For more information please visit www.metherapeutics.com and the Company's profile on SEDAR+ at www.sedarplus.ca.

We seek Safe Harbor.